| Literature DB >> 25738170 |
Inês Brás Marques1, Stuart Flanagan1, Heather Noble1, Gavin Giovannoni1, Monica Marta1.
Abstract
Entities:
Year: 2015 PMID: 25738170 PMCID: PMC4335817 DOI: 10.1212/NXI.0000000000000074
Source DB: PubMed Journal: Neurol Neuroimmunol Neuroinflamm ISSN: 2332-7812
FigureBrain MRI of the patient throughout the disease course
(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis treatment (b). (B) Brain MRI at admission showing increase in lesion number and contrast uptake. (C) Brain MRI showing radiologic response to toxoplasmosis treatment. (D) Brain MRI after progressive clinical deterioration showing increase in lesion number and multiple new enhancing vessels in the perforator and peripheral distribution of middle cerebral artery territories. (E) Brain MRI after 2 months of foscarnet treatment. Despite significant clinical improvement, radiologic lesions persist.